Abstract

FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns

Author(s): Allen Loyd V Jr

Issue: Jan/Feb 1999 - Dental Compounding

Page(s): 25-29

Download in electronic PDF format for $75
  • FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns Page 1
  • FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns Page 2
  • FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns Page 3
  • FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns Page 4
  • FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns Page 5

Abstract

The US Food and Drug Administration has proposed that drug products listed in the table provided here be included on the list of drug products withdrawn or removed from the market because they have been found to be unsafe or ineffective. Therefore, compounding a drug product on this list would not be covered by the exemption provided in Section 503A(a) of the Federal Food and Drug Administration Modernization Act of 1997. The list originally appeared in the October 8, 1998, Federal Register (63[195]:54083-54087). Listings are mostly alphabetical. Reasons for withdrawal and withdrawal dates are also provided.

Related Keywords

  • Safety
  • Efficacy

Related Categories

  • LEGAL

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 1999
Pg. 25-29
FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns
Author(s): Allen Loyd V Jr
Nov/Dec 2020
Pg. 451-458
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Author(s): Allen W Chris, Greeson Nicole MH, Mixon William
Jul/Aug 2004
Pg. 313-319
Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Author(s): Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Sep/Oct 2020
Pg. 356
Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 270-276
Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
Sep/Oct 2020
Pg. 371-379
Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
Jan/Feb 2015
Pg. 57-58
Basics of Compounding: The Revised "Not to Compound List"
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 111-116
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Author(s): Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Author(s): Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
May/Jun 2013
Pg. 182-190
Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists
Author(s): Mixon Bill, Nain John
Sep/Oct 2018
Pg. 387-398
Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations
Author(s): Ashe Krystina, Baskett Dustin
May/Jun 2019
Pg. 182-186
How to Develop and Maintain a Hazardous Drug List
Author(s): Dillon L Rad
Mar/Apr 2017
Pg. 118-124
Quality Control: (Material) Safety Data Sheets
Author(s): Allen Loyd V Jr
Jan/Feb 2002
Pg. 60-61
Safety for Employees in the Compounding Work Area
Author(s): Allen Loyd V Jr
Nov/Dec 2013
Pg. 485-489
Quality Control Analytical Methods: A Growing Codependency: Compounding Pharmacy and Safety
Author(s): Prince Bryan, Lundeval Jeremy
Sep/Oct 2021
Pg. 358-362
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Author(s): Cabaleiro Joe
Jan/Feb 2015
Pg. 6-12
Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review
Author(s): Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
Nov/Dec 2016
Pg. 477-479
The "Lists": What Do They Mean?
Author(s): Voliva John
Jul/Aug 2015
Pg. 311-313
Basics of Compounding: The "Negative" List
Author(s): Allen Loyd V